Home >>Botany >> Schisandra chinensis

Schisandra chinensis

Schisandra chinensis

1. The products in our compound library are selected from thousands of unique natural products; 2. It has the characteristics of diverse structure, diverse sources and wide coverage of activities; 3. Provide information on the activity of products from major journals, patents and research reports around the world, providing theoretical direction and research basis for further research and screening; 4. Free combination according to the type, source, target and disease of natural product; 5. The compound powder is placed in a covered tube and then discharged into a 10 x 10 cryostat; 6. Transport in ice pack or dry ice pack. Please store it at -20 °C as soon as possible after receiving the product, and use it as soon as possible after opening.

Natural products/compounds from  Schisandra chinensis

  1. Cat.No. Product Name CAS Number COA
  2. BCN2674 Negsehisandrin G1023744-69-5 Instructions
  3. BCN5362 Anwulignan107534-93-0 Instructions
  4. BCN5808 Wulignan A1117047-76-4 Instructions
  5. BCN3315 Schisanwilsonin H1181216-83-0 Instructions
  6. BCN5548 Schisanwilsonin I1181216-84-1 Instructions
  7. BCN1521 rel-(8R,8'R)-dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan178740-32-4 Instructions
  8. BCN7847 Chamigrenal19912-84-6 Instructions
  9. BCN1240 Dehydrodiisoeugenol2680-81-1 Instructions
  10. BCN5979 Caffeic acid331-39-5 Instructions
  11. BCN5590 Daidzein486-66-8 Instructions
  12. BCN8390 Myristic acid544-63-8 Instructions
  13. BCN2851 Quercetin 3-O-beta-D-xylopyranoside549-32-6 Instructions
  14. BCN5794 Gomisin A58546-54-6 Instructions
  15. BCN1023 Schisantherin B58546-55-7 Instructions
  16. BCN1024 Schisantherin A58546-56-8 Instructions
  17. BCN2268 Gomisin D60546-10-3 Instructions
  18. BCN1022 Schizandrin B61281-37-6 Instructions
  19. BCN1021 Schizandrin A61281-38-7 Instructions
  20. BCN1198 Schisandrin C61301-33-5 Instructions
  21. BCN2269 Gomisin G62956-48-3 Instructions
  22. BCN6766 Schisantherin E64917-83-5 Instructions
  23. BCN3902 Gomisin H66056-20-0 Instructions
  24. BCN2843 Angeloylgomisin H66056-22-2 Instructions
  25. BCN2270 Gomisin J66280-25-9 Instructions
  26. BCN2508 Schisanhenol69363-14-0 Instructions
  27. BCN2875 Gomisin O72960-22-6 Instructions
  28. BCN5815 Schisandrin A7432-28-2 Instructions
  29. BCN1029 D-(-)-Quinic acid77-95-2 Instructions
  30. BCN7818 Chicanine78919-28-5 Instructions
  31. BCX0642 Isokadsuranin82467-52-5 Instructions
  32. BCN7361 Angeloylgomisin O83864-69-1 Instructions
  33. BCN2863 (-)-Holostyligone887501-28-2 Instructions
  34. BCN3316 Schisandrone98619-25-1 Instructions
  35. BCN4537 3,4-Dihydroxybenzoic acid99-50-3 Instructions

References

[Optimization of Aqueous Two-Phase Extraction of Polysaccharide from Schisandra chinensis Using Response Surface Methodology with Box-Behnken Design].[Pubmed: 30091354]


To optimize the extraction condition of polysaccharide from Schisandra chinensis. Aqueous two-phase extraction( ATPE) method was used, based on Box-Behnken design with Response surface methodology( BBD-RSM).


Protective effects of Schisandrin on high glucose-induced changes of RhoA and eNOS activity in human umbilical vein endothelial cells.[Pubmed: 30031586]


Schisandrin, derived from the Chinese medicinal herb Schisandra chinensis, has been found to confer protective effects on circulation systems. But the underlying molecular mechanisms remain unclear. The aim of this study was to investigate the effects of a high level of glucose on RhoA and eNOS activity in human umbilical vein endothelial cells(HUVECs) and how Schisandrin plays a role in mediating these effects. To find the optimal treatment time, HUVECs were cultured at a high glucose concentration (30 mM) for different lengths of time (0, 12, 24, and 48 h). Subsequently, the cells were randomized into five groups: a normal group, a high glucose group, and three high glucose groups that were given different doses (5, 10, and 20 μM) of Schisandrin. The cells were pretreated with Schisandrin for 24 h before stimulation with high glucose. The morphology of HUVECs in the various groups was assessed under a light microscope. Immunocytochemical staining was used to detect the level of p-MYPT1 expression. The levels of RhoA activity were determined using the RhoA Activation Assay Biochem Kit. The levels of eNOS activity were examined using a nitrate reduction test. The results showed that in the high glucose group, the activity of RhoA was increased and the activity of eNOS was reduced, thus decreasing the secretion of NO. However, after pretreatment with Schisandrin (10, 20 μM), the activity of RhoA was inhibited and the activity of eNOS increased, which led to an increase in NO production compared with the high glucose group. There was no evident difference between the 5 μM Schisandrin group and the high glucose group. Taken together, these findings indicate that Schisandrin can improve the function of endothelial cells by lowering the activity of RhoA/Rho kinase and raising both the activity of eNOS and the production of NO.